Charles Schwab
SMMT icon

Charles Schwab’s Summit Therapeutics SMMT Stock Holding History

Charles Schwab’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2M Buy
976,851
+15,984
+2% +$283K ﹤0.01% 1984
2026
Q1 		$18.2M Buy
960,867
+68,238
+8% +$1.1M ﹤0.01% 1792
2025
Q4 		$15.6M Buy
892,629
+16,239
+2% +$306K ﹤0.01% 1903
2025
Q3 		$18.1M Sell
876,390
-415,281
-32% -$10.1M ﹤0.01% 1787
2025
Q2 		$27.5M Sell
1,291,671
-169,046
-12% -$3.85M ﹤0.01% 1487
2025
Q1 		$28.2M Sell
1,460,717
-24,355
-2% -$489K 0.01% 1434
2024
Q4 		$26.5M Buy
1,485,072
+52,359
+4% +$1.01M ﹤0.01% 1542
2024
Q3 		$31.4M Buy
1,432,713
+497,984
+53% +$6.96M 0.01% 1436
2024
Q2 		$7.29M Sell
934,729
-81,816
-8% -$442K ﹤0.01% 2186
2024
Q1 		$4.21M Buy
1,016,545
+62,699
+7% +$249K ﹤0.01% 2342
2023
Q4 		$2.49M Buy
953,846
+13,050
+1% +$26.8K ﹤0.01% 2547
2023
Q3 		$1.76M Buy
940,796
+629,726
+202% +$1.2M ﹤0.01% 2638
2023
Q2 		$781K Buy
311,070
+296,489
+2,033% +$541K ﹤0.01% 2851
2023
Q1 		$25.5K Sell
14,581
-531
-4% -$1.45K ﹤0.01% 3478
2022
Q4 		$64.2K Buy
+15,112
New +$27.5K ﹤0.01% 3313
2022
Q2 		– Sell
-61,313
Closed -$151K – 3633
2022
Q1 		$151K Buy
61,313
+6,280
+11% +$15.8K ﹤0.01% 3354
2021
Q4 		$149K Hold
55,033
– – ﹤0.01% 3402
2021
Q3 		$276K Buy
55,033
+7,385
+15% +$53K ﹤0.01% 3284
2021
Q2 		$356K Buy
+47,648
New +$313K ﹤0.01% 3217

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Charles Schwab's SMMT Position: Q2 2026 in Review

Charles Schwab increased its Summit Therapeutics (SMMT) stake by 1.7% in Q2 2026, buying an estimated $283K and bringing the position to 976,851 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Charles Schwab first reported a position in SMMT in Q2 2021 and has held it in 19 quarters since. The position peaked at $31.4M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Charles Schwab held 976,851 shares of Summit Therapeutics worth $14.2M as of Q2 2026.
  • Charles Schwab bought 15,984 Summit Therapeutics shares in Q2 2026, an estimated $283K.
  • Summit Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1984 holding.
  • Charles Schwab first reported a position in Summit Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Charles Schwab's Summit Therapeutics position peaked at $31.4M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.